Ainos (AIMD) AI Stock Analysis

• Market Cap: $8.03M
• Dividend Yield: N/A
• Average Volume (3M): 189.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: -83.02%
• EPS Growth: 47.29%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -1.69
• Shares Outstanding: 15,433,257
• 10 Day Avg. Volume: 133,044
• 30 Day Avg. Volume: 189,487
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 394.60
• Price to Cash Flow (P/CF): -2.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Ainos struggles with financial instability, marked by declining revenues and persistent losses. While short-term technical indicators show some improvement, the long-term outlook remains weak. Valuation concerns further exacerbate the company's challenges, highlighting significant risks for investors.

Ainos Business Overview & Revenue Model

Company Description

Ainos, Inc. (AIMD) is a cutting-edge biotechnology company specializing in the development of novel medical diagnostic solutions and therapeutic products. The company operates within the healthcare and biotechnology sectors, focusing on the advancement of innovative technologies, particularly in the areas of infectious diseases, oncology, and personalized medicine. Ainos aims to enhance patient care by leveraging proprietary technologies to deliver accurate diagnostics and effective treatments.

How the Company Makes Money

Ainos generates revenue through the development and commercialization of its proprietary diagnostic and therapeutic products. The company primarily makes money by selling these products to healthcare providers, research institutions, and pharmaceutical companies. Key revenue streams include sales of diagnostic devices, licensing of technology, and collaborations with strategic partners in the healthcare industry. Ainos also engages in research and development partnerships that may provide additional funding and revenue opportunities. The company's earnings are significantly influenced by its ability to innovate and bring new products to market, as well as its strategic alliances with other organizations in the healthcare sector.

Ainos Financial Statement Overview

Summary

Ainos faces considerable financial difficulties with declining revenues, persistent losses, and negative cash flows. While there are slight improvements in equity and financing, the company's financial health is weak, characterized by high leverage and operational inefficiencies. Urgent strategic adjustments are needed to stabilize and reverse the negative financial trajectory.

Income Statement

Ainos has experienced a severe decline in revenue over the years, with Total Revenue dropping to zero in the most recent year. This, coupled with negative gross and net profit margins, indicates significant operational challenges and profitability issues. There is also a lack of revenue growth, as recent results reflect a substantial decrease from previous years.

Balance Sheet

Ainos has a high debt-to-equity ratio, indicating leveraged financial structure, but the equity position has improved from negative to positive over time. However, the equity ratio remains relatively low, reflecting limited financial stability. Return on Equity is negative due to ongoing losses, suggesting inefficiencies in generating returns on shareholder investment.

Cash Flow

The company's cash flow metrics reveal persistent negative operating and free cash flows, highlighting liquidity challenges. Despite some improvements in financing activities, operating cash flow remains significantly negative compared to net income, indicating operational inefficiencies and cash flow constraints.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
20.73K	122.11K	3.52M	594.56K	16.56K
	Gross Profit
-31.87K	-253.73K	1.41M	410.38K	5.29K
	EBIT
-13.84M	-13.21M	-13.98M	-3.87M	-1.44M
	EBITDA
-9.44M	-8.77M	-9.14M	-1.83M	-1.43M
	Net Income Common Stockholders
-14.86M	-13.77M	-14.04M	-3.90M	-1.46M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.89M	1.89M	1.85M	1.75M	22.25K
	Total Assets
28.82M	31.84M	37.11M	40.82M	260.29K
	Total Debt
12.00M	5.96M	1.27M	3.62M	953.00K
	Net Debt
8.11M	4.08M	-584.74K	1.87M	930.76K
	Total Liabilities
13.30M	7.39M	2.48M	30.63M	1.10M
	Stockholders Equity
15.52M	24.45M	34.63M	10.20M	-838.28K
Cash Flow		Free Cash Flow
-5.83M	-4.79M	-3.66M	-1.39M	-506.79K
	Operating Cash Flow
-5.81M	-4.69M	-3.02M	-1.25M	-499.55K
	Investing Cash Flow
-125.29K	-101.53K	-630.18K	-180.52K	-7.24K
	Financing Cash Flow
8.03M	4.92M	3.83M	3.15M	120.00K

Ainos Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Positive. The current price of 0.64 is above the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.56, and above the 200-day MA of 0.57, indicating a bullish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.03 is Neutral, neither overbought nor oversold. The STOCH value of 29.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIMD.

Ainos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INVA	66 Neutral	$1.07B	83.75	3.42%	―	14.88%	-86.70%
MNKD	58 Neutral	$1.41B	50.93	-35.00%	―	43.50%	―
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
AVDL	42 Neutral	$701.53M	―	-60.44%	―	504.79%	74.24%
XOMA	39 Underperform	$241.33M	―	-16.20%	―	498.72%	49.92%
AIMD	25 Underperform	$8.03M	―	-74.38%	―	-83.02%	47.29%

Ainos Corporate Events

Ainos Partners with Taiwan Tanabe for VELDONA® Expansion

Ainos, Inc. has announced a strategic collaboration with Taiwan Tanabe Seiyaku to enhance the production and market presence of its innovative Sjögren’s syndrome drug, VELDONA®. This partnership, based on a Memorandum of Understanding, aims to address the growing demand for effective treatments in the autoimmune disease sector, leveraging Taiwan Tanabe’s pharmaceutical expertise for manufacturing and promotion. Ainos anticipates this venture will accelerate VELDONA®’s market introduction, offering significant growth potential and opening new opportunities in the field of autoimmune therapies.